[1] Criner GJ, et al. Anti-Granulocyte-Macrophage Colony-Stimulating Factor Monoclonal Antibody Gimsilumab for COVID-19 Pneumonia: A Randomized, Double-Blind, Placebo-controlled Trial. Am J Respir Crit Care Med. 2022 Jun 1;205(11):1290-1299. DOI:
10.1164/rccm.202108-1859OC[2] Crotti C, et al. Spotlight on mavrilimumab for the treatment of rheumatoid arthritis: evidence to date. Drug Des Devel Ther. 2017 Jan 13;11:211-223. DOI:
10.2147/DDDT.S104233